A Preclinical Consortium Approach for Assessing the Efficacy of Combined Anti-CD3 Plus IL-1 Blockade in Reversing New-Onset Autoimmune Diabetes in NOD Mice

There is an ongoing need to develop strategic combinations of therapeutic agents to prevent type 1 diabetes (T1D) or to preserve islet β-cell mass in new-onset disease. Although clinical trials using candidate therapeutics are commonly based on preclinical studies, concern is growing regarding the r...

Descripción completa

Detalles Bibliográficos
Autores principales: Gill, Ronald G., Pagni, Philippe P., Kupfer, Tinalyn, Wasserfall, Clive H., Deng, Songyan, Posgai, Amanda, Manenkova, Yulia, Bel Hani, Amira, Straub, Laura, Bernstein, Philip, Atkinson, Mark A., Herold, Kevan C., von Herrath, Matthias, Staeva, Teodora, Ehlers, Mario R., Nepom, Gerald T.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Diabetes Association 2016
Materias:
Immunology and Transplantation
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5860426/
https://www.ncbi.nlm.nih.gov/pubmed/26718498
http://dx.doi.org/10.2337/db15-0492

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5860426/
https://www.ncbi.nlm.nih.gov/pubmed/26718498
http://dx.doi.org/10.2337/db15-0492

Ejemplares similares